Insider Selling: AbbVie (NYSE:ABBV) EVP Sells 32,710 Shares

Key Points

• AbbVie EVP Nicholas Donoghoe sold 32,710 shares at an average price of $250, generating approximately $8.18 million. His remaining stake fell 30.53% to 74,430 shares.
• AbbVie reported quarterly EPS of $3.65, beating estimates of $3.61, while revenue rose 10.2% year over year to $16.99 billion. The company set third-quarter 2026 EPS guidance at $3.84–$3.88.
• The stock carries a “Moderate Buy” consensus rating, with analysts’ average price target at $275.73 versus a cited market price of $259.01. AbbVie also pays a quarterly dividend of $1.73 per share, yielding about 2.7%.

AbbVie Inc. (NYSE:ABBV - Get Free Report) EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

AbbVie Price Performance

NYSE:ABBV opened at $259.01 on Wednesday. The stock has a market capitalization of $457.63 billion, a PE ratio of 73.17, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The business's 50-day simple moving average is $246.17 and its 200-day simple moving average is $226.63.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company's quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts expect that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's dividend payout ratio is currently 195.48%.

Institutional Trading of AbbVie

Several institutional investors and hedge funds have recently bought and sold shares of ABBV. Ranch Capital Advisors Inc. boosted its holdings in shares of AbbVie by 37.0% in the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company's stock valued at $3,238,000 after buying an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK raised its stake in AbbVie by 11.2% during the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company's stock worth $112,516,000 after acquiring an additional 45,132 shares during the period. Calamos Advisors LLC lifted its position in shares of AbbVie by 3.4% during the 4th quarter. Calamos Advisors LLC now owns 466,290 shares of the company's stock valued at $106,543,000 after acquiring an additional 15,458 shares during the period. Wedge Capital Management L L P NC lifted its stake in shares of AbbVie by 7.5% during the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company's stock valued at $33,865,000 after acquiring an additional 9,380 shares during the period. Finally, Axecap Investments LLC lifted its holdings in shares of AbbVie by 713.2% during the 4th quarter. Axecap Investments LLC now owns 16,320 shares of the company's stock worth $3,729,000 after acquiring an additional 14,313 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. UBS Group lifted their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research report on Monday, July 13th. Weiss Ratings upgraded shares of AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research report on Tuesday, August 4th. HSBC reiterated a "buy" rating and issued a $300.00 target price on shares of AbbVie in a report on Monday, July 6th. BNP Paribas Exane boosted their price objective on AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a report on Tuesday, August 11th. Finally, Canaccord Genuity Group increased their price target on AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $275.73.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source